Suzy Madar, Author at Mallesons Pulse Blog

Digging too deep: When patent amendments become an abuse of process

24 April 2026

This is a short note to report on a successful interlocutory application seeking a declaration that a patent amendment amounted to an abuse of process.

Read on

The TGA’s medicinal cannabis products review: what stakeholders said and what comes next

19 March 2026

By Suzy Madar, Rowan Tan, Damien MacRae

The Therapeutic Goods Administration (TGA) has released its response to the feedback it received to its consultation on the safety and regulatory oversight of unapproved medicinal cannabis products.

Read on

CPC v Apple: Appeal in funded patent litigation

5 March 2026

By Suzy Madar, Tim Craven, Christine Porter

CPC Patents Technologies’ (CPC) appeal of the Federal Court’s decision in CPC Patent Technologies Pty Ltd v Apple Pty Limited [2025] FCA 489 was heard in the Federal Court earlier this week.

Read on

Federal Court grants urgent interlocutory injunction in dapagliflozin dispute

24 February 2026

By Kate Hay, Suzy Madar, Jacob Flynn, Lily McCubbin

On 16 February 2026, the Federal Court of Australia granted an urgent interlocutory injunction restraining Pharmacor from launching and listing generic dapagliflozin products on the PBS.

Read on

New TGA guidance on the regulation of AI-based software medical devices

17 February 2026

By Suzy Madar, Luke Hawthorne, Penny Henderson

Opportunities for the application of AI in health and life sciences continue to grow.

Read on

Special leave in Aristocrat refused: Australia’s approach to patentability of CIIs settled

11 February 2026

By Suzy Madar, Kate Hay, Jacob Flynn, Rowan Tan

Following the High Court’s refusal of special leave to the Commissioner of Patents on 5 February 2026, Australia now has a clear position on computer-implemented inventions (CIIs): the Full Federal Court’s September 2025 articulation of the test in Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents[1] remains the settled law.

Read on

Federal Court grants first preliminary injunction to pharma patentee in 7 years

28 January 2026

By Suzy Madar, Kate Hay, Matthew Swinn, Jacob Flynn, Lily McCubbin

On 5 December 2025, the Federal Court of Australia granted an interlocutory injunction restraining the launch and Pharmaceutical Benefits Scheme (PBS) listing of generic long-acting injectable (LAI) paliperidone palmitate products.

Read on

Australia reformulates its position on patent term extensions

15 December 2025

By Matthew Swinn, Kate Hay, Suzy Madar, Jacob Flynn

The Full Federal Court of Australia has determined that pharmaceutical formulations are not eligible for patent term extension in Australia.

Read on

Collaborating? Here’s how to avoid a web of IP issues

22 August 2025

By Suzy Madar, Kate Hay, Jacob Flynn, Emily King

Commercial collaboration can create unbeatable opportunities for innovation and securing return on investment.

Read on

A new code for care: decoding the impact of Genomics Australia

19 August 2025

By Suzy Madar, Emily King

The Australian health sector is entering a transformative phase with the official launch of Genomics Australia on 1 July 2025 and a new Australian Health Genomics Commissioner.

Read on

Posts From This Author